Gilead Sciences’ move to launch generic versions of two hepatitis C treatments could motivate states to eliminate restrictions on their Medicaid and inmate populations.
Gilead’s generic hep C drugs may increase access through Medicaid
Gilead Sciences’ move to launch generic versions of two hepatitis C treatments could motivate states to eliminate restrictions on their Medicaid and inmate populations.